Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
97.34
-0.73 (-0.74%)
Mar 4, 2026, 10:56 AM EST - Market open
Incyte Revenue
In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth. Incyte had revenue of $1.51B in the quarter ending December 31, 2025, with 27.84% growth.
Revenue (ttm)
$5.14B
Revenue Growth
+21.22%
P/S Ratio
3.80
Revenue / Employee
$1,807,750
Employees
2,844
Market Cap
19.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.03M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.67M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.72% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genmab | 3.72B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
| BridgeBio Pharma | 502.08M |
INCY News
- 1 day ago - Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 5 days ago - Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata - PRNewsWire
- 13 days ago - Incyte Remains Undervalued As Opzelura And Niktimvo Scale - Seeking Alpha
- 15 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 19 days ago - Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells - Seeking Alpha
- 20 days ago - Incyte: Why The Market Is Overreacting To A Guidance 'Miss' - Seeking Alpha
- 21 days ago - Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Incyte weak 2026 revenue forecast heightens Jakafi patent concerns - Reuters